What Is Lymphoma: Types, Symptoms, and Statistics

Lymphoma is a general term for cancer in the lymph system. The lymph system is made up of many cells and organs, including the lymph nodes, thymus gland, spleen, and liver. This system produces B-Cells and T-Cells, which make up your body’s immune system. Since these cells travel between the lymphatic system and circulatory system while fighting infections and viruses, lymphomas are blood-related cancers.

Types

There are two main categories of lymphomas: Hodgkin’s lymphoma (aka Hodgkin’s disease or Hodgkin lymphoma) and Non-Hodgkin’s lymphomas (NHL). Hodgkin’s disease is a very specific type of cancer that involves a mutation in Reed-Sternberg cells.

Non-Hodgkin’s Lymphomas involve mutations in the body’s B-Cells and T-Cells. B-Cell Lymphomas account for over 80% of all NHL. T-Cell Lymphomas make up the rest.

Symptoms

Unfortunately, lymphoma doesn’t have many identifying symptoms; those that exist are also indicators for other, more common diseases. For example, typical lymphoma symptoms include:

  • swollen lymph nodes in the neck, armpit, or groin; usually painless
  • fever and/or night sweats
  • unexplained weight loss
  • fatigue
  • chest pain
  • loss of appetite is less common symptom of some more aggressive lymphomas of the GI tract

Statistics

According to the Leukemia & Lymphoma Society:

  • About 139,860 people living in the United States will be diagnosed with lymphoma, leukemia, or myeloma in 2009. This accounts for 9.5% of expected cancer diagnoses.
  • 12.2 out of every 100,000 people in the world will be diagnosed with leukemia.
  • 19.5 out of every 100,000 people in the world will be diagnosed with Non-Hodgkin’s Lymphoma.
  • 2.8 out of every 100,000 people in the world will be diagnosed with Hodgkin’s Disease.
  • The mortality rate of leukemia and lymphoma has decreased as the survival rate increased due to improved treatments.

Other common statistics reflect that:

  • Males are typically affected more than females.
  • Hodgkin’s Lymphoma is more common in younger patients than other types of lymphoma.
  • Non-Hodgkin’s Lymphomas are more prevalent in patients over 50.

In summary, lymphoma of any type is a systemic disease. It is treatable with generally high survival rates but the road to diagnosis, prognosis and recovery will take time and patience. We hope that these pages can help you along the way.

Related Articles

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap